Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Cellular Physiology|February 6, 2008
ERalpha and AP-1 interact in vivo with a specific sequence of the F promoter of the human ERalpha gene in osteoblastsElisabetta Lambertini, Elisa Tavanti, Elena Torreggiani, et al.
Pharmacogenomics|November 25, 2016
Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patientsClaudia M Hattinger, Serena Vella, Elisa Tavanti, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 21, 2016
Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcomaClaudia Maria Hattinger, Elisa Tavanti, Marilù Fanelli, et al.
Cell Biology International|October 16, 2007
Evaluation of chemokine and cytokine profiles in osteoblast progenitors from umbilical cord blood stem cells by BIO-PLEX technologyLetizia Penolazzi, Elisabetta Lambertini, Elisa Tavanti, et al.
Apoptosis : an International Journal on Programmed Cell Death|March 1, 2008
Human osteoclasts differentiated from umbilical cord blood precursors are less prone to apoptotic stimuli than osteoclasts from peripheral bloodLetizia Penolazzi, Barbara Pocaterra, Elisa Tavanti, et al.
Molecular Pharmacology|March 29, 2007
Induction of estrogen receptor alpha expression with decoy oligonucleotide targeted to NFATc1 binding sites in osteoblastsLetizia Penolazzi, Margherita Zennaro, Elisabetta Lambertini, et al.
Expert Opinion on Emerging Drugs|May 30, 2015
Advances in emerging drugs for osteosarcomaClaudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, et al.
Experimental Cell Research|March 14, 2007
Human estrogen receptor alpha gene is a target of Runx2 transcription factor in osteoblastsElisabetta Lambertini, Letizia Penolazzi, Elisa Tavanti, et al.
Expert Review of Molecular Diagnostics|October 17, 2018
Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?Claudia Maria Hattinger, Maria Pia Patrizio, Elisa Tavanti, et al.
Plos One|November 30, 2016
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsSerena Vella, Elisa Tavanti, Claudia Maria Hattinger, et al.
Pageof 2